Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Genocea Biosciences (GNCA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 44,268
  • Shares Outstanding, K 86,630
  • Annual Sales, $ 0 K
  • Annual Income, $ -56,710 K
  • 36-Month Beta 1.03
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.29
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.21
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/01/18
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.10
  • Number of Estimates 3
  • High Estimate -0.08
  • Low Estimate -0.13
  • Prior Year -0.59
  • Growth Rate Est. (year over year) +83.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.49 +4.08%
on 09/18/18
0.66 -22.73%
on 08/24/18
-0.11 (-17.74%)
since 08/20/18
3-Month
0.49 +4.08%
on 09/18/18
1.00 -49.00%
on 06/22/18
-0.48 (-48.48%)
since 06/20/18
52-Week
0.49 +4.08%
on 09/18/18
5.45 -90.64%
on 09/25/17
-4.76 (-90.32%)
since 09/20/17

Most Recent Stories

More News
Genocea Biosciences Sees Hammer Chart Pattern: Time to Buy?

Genocea Biosciences has been struggling lately, but the selling pressure may be coming to an end soon.

GNCA : 0.51 (unch)
Genocea Biosciences: 2Q Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Genocea Biosciences Inc. (GNCA) on Thursday reported a loss of $4.4 million in its second quarter.

GNCA : 0.51 (unch)
Genocea Reports Second Quarter 2018 Financial and Operating Results

Neoantigen vaccine program GEN-009 Phase 1/2a clinical trial underway

GNCA : 0.51 (unch)
Genocea Biosciences, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / August 2, 2018 / Genocea Biosciences, Inc. (NASDAQ: ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 2, 2018 at 9:00 AM Eastern Time....

GNCA : 0.51 (unch)
Complimentary Technical Snapshots on Incyte and Three More Biotech Stocks

Stock Research Monitor: FPRX, GNCA, and IMMU

FPRX : 14.12 (-0.84%)
GNCA : 0.51 (unch)
IMMU : 22.53 (+2.08%)
Genocea Biosciences: 1Q Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Genocea Biosciences Inc. (GNCA) on Thursday reported a loss of $15.3 million in its first quarter.

GNCA : 0.51 (unch)
Genocea Reports First Quarter 2018 Financial and Operating Results

- Company files IND for lead neoantigen vaccine program, GEN-009 -

GNCA : 0.51 (unch)
Market Trends Toward New Normal in City Office REIT, Malibu Boats, Vical, Renasant, Genocea Biosciences, and Lindsay -- Emerging Consolidated Expectations, Analyst Ratings

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of City Office REIT, Inc. (NYSE:CIO),...

MBUU : 52.67 (-0.42%)
VICL : 1.39 (+1.46%)
GNCA : 0.51 (unch)
CIO : 12.27 (+1.49%)
RNST : 44.30 (+0.80%)
LNN : 99.06 (+2.18%)
Genocea Files Investigational New Drug Application for Neoantigen Cancer Vaccine Candidate GEN-009

- Company plans to initiate Phase 1/2a clinical program later this year -

GNCA : 0.51 (unch)
Genocea Presents Data at AACR Annual Meeting Further Highlighting Advantages of ATLAS Platform in Identification of Neoantigens over in silico Methods

- ATLAS data demonstrate in silico methods miss most empirically confirmed neoantigens -

GNCA : 0.51 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade GNCA with:

Business Summary

Genocea Biosciences, Inc. is involved in developing vaccines. The company's proprietary discovery platform consists of AnTigen Lead Acquisition System which designs vaccines that stimulate T cell immunity. Its product portfolio which are in different clinical trials consist of GEN-003, HSV-2 infections,...

See More

Key Turning Points

2nd Resistance Point 0.53
1st Resistance Point 0.52
Last Price 0.51
1st Support Level 0.50
2nd Support Level 0.50

See More

52-Week High 5.45
Fibonacci 61.8% 3.56
Fibonacci 50% 2.97
Fibonacci 38.2% 2.38
Last Price 0.51
52-Week Low 0.49

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar